Infinity to Present At Upcoming Conferences
02. September 2009 07:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 2, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that management will...
Infinity Reports Recent R&D Highlights and Second Quarter 2009 Results
05. August 2009 16:15 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 5, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today reviewed recent R&D highlights,...
Infinity Announces Second Quarter 2009 Results Conference Call
30. Juli 2009 06:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., July 30, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced today that Infinity management...
Infinity Paper On Discovery of Its Novel Hedgehog Inhibitor, IPI-926, Published in Journal of Medicinal Chemistry
23. Juli 2009 16:40 ET
|
Infinity Pharmaceuticals, Inc.
-- Paper Features Chemistry and Preclinical Data Leading to
Discovery of IPI-926 - Currently in Phase 1 Development --
-- Publication Follows Recent Paper in Science Demonstrating
...
Infinity Pharmaceuticals Added to Russell 2000(r) Index
29. Juni 2009 06:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 29, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it was added to the...
Infinity Reports Encouraging Clinical Data for IPI-504 at ASCO 2009
30. Mai 2009 14:00 ET
|
Infinity Pharmaceuticals, Inc.
Phase 2 Data Show Partial Responses and Generally Well-Tolerated
Safety Profile in Patients with Advanced Non-Small Cell Lung Cancer
Phase 1 Study Demonstrates Combinability of IPI-504...
New Paper in Science Features Infinity's IPI-926 Hedgehog Pathway Inhibitor as a Promising New Approach in Chemo-Resistant Pancreatic Cancer
29. Mai 2009 06:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 29, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced the recent publication of a new...
Infinity Pharmaceuticals Named Winner of The Scientist's 'Best Places to Work in Industry' and Featured in Boston Business Journal's Best Places to Work 2009 Survey
27. Mai 2009 13:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 27, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it has been named one...
Clinical Data From Infinity's Hsp90 Chaperone Inhibitor Program to be Presented During ASCO Meeting
13. Mai 2009 07:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 13, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be reporting...
Infinity Reports Recent Pipeline Developments and First Quarter 2009 Results
04. Mai 2009 16:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 4, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today reviewed recent clinical...